Indeed, low levels of sPD-L1 at baseline correlated with a better clinical benefit of NSCLC patients treated with anti-PD-1 mAb [29] and with a longer time before the progression of disease in melanoma patients treated with the anti-CTLA-4 mAb ipilimumab [19]. Here, CTLA4 is linked to melanoma.